Media Centre

Home to all the latest news, featured stories, media assets and contacts to help you understand the Diversey story.

MEDIA RELEASE: Diversey's Oxivir® Five 16 & Virex II - Kills SARS-CoV-2 (COVID-19 virus)!

The Therapeutic Goods Administration (TGA) has recognised disinfectants as critical in preventing the spread of COVID-191. Following our previous announcement that Oxivir® Tb had gained TGA approval for a COVID-19 label claim, Diversey Australia and New Zealand are proud to announce Oxivir® Five 16 and Virex® II are now approved with the label claim ‘Kills SARS-CoV-2 (COVID-19 virus)’. This new claim is in addition to the current comprehensive list of claims under ARTG 286618 for Oxivir® Five 16 and ARTG 153031 for Virex II. 

“We are pleased to announce our Oxivir Five 16 and Virex II ranges have now gained TGA approval for a claim to kill COVID-19. This added claim offers confidence to our valued customers during this uncertain time. As a global company, Diversey continues to work tirelessly in product development, sourcing and testing to assist in controlling the spread of COVID-19.” Said Wayne Hill, Managing Director, Diversey ANZ.

Oxivir Five 16 is an Accelerated Hydrogen Peroxide® (AHP®) based hospital grade cleaner disinfectant effective against a wide variety of pathogenic micro-organisms including viruses, bacteria, antibiotic-resistant bacteria, fungi, mould and mildew. Oxivir Five 16 kills pathogens including VRE, MRSA, Klebsiella, Acinetobacter, Pseudomonas, E.coli, Norovirus, Hepatitis B, Influenza A, RSV, Human Coronavirus 229E. Kills SARS-CoV-2 (COVID-19 virus). Oxivir Five 16 delivers fast, effective cleaning and disinfecting performance in one step.

Virex II is low odour quaternary based hospital grade disinfectant cleaner that provides broad spectrum germicidal activity and kills SARS-CoV-2 (COVID-19 virus), HIV-1, HBV, VRE, MRSA, Avian Influenza Type A, Human Coronavirus 229E, controls mould and mildew and more.

As cases of COVID-19 grow, the demand and urgency for cleaning and disinfection requirements has reached unprecedented levels. It was important we worked with the Australian TGA to add the COVID-19 claim to our Oxivir Tb, Oxivir Five 16 and Virex II range of products. It was also important we communicate this information to our valued customers. Whilst we celebrate this announcement, our stock level challenges persist due to unprecedented demands. We ask for patience as we service multiple essential services including healthcare and aged care facilities”. Noted Debbie Walker, Marketing Manager ANZ.

Diversey has been, and always will be, a pioneer and facilitator for life. We constantly deliver revolutionary cleaning and hygiene technologies that provide total confidence to our customers across all of our global sectors.

For more information on contact:
Diversey Australia
Healthcare Sector Lead: David Purnell
Phone: 0411 075 732 or email This email address is being protected from spambots. You need JavaScript enabled to view it.
29 Chifley Street, Smithfield NSW 2164 AUSTRALIA
Diversey New Zealand
Healthcare Sector Lead: Hazel Wright
Phone: 064 21 853 161 or email This email address is being protected from spambots. You need JavaScript enabled to view it.
24 Bancroft Cres, Glendene, Auckland, NEW ZEALAND

Reference: 1.
®Diversey 2020. All rights reserved. AHP® and Design and Oxivir® are trademarks of Diversey, Inc.